United Therapeutics (Priority Review Voucher) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

United Therapeutics (Priority Review Voucher) General Information

Description

A pediatric disease priority review voucher. The voucher acts as an incentive for development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 1040 Spring Street
  • Silver Spring, MD 20910
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
AbbVie
Corporate Office
  • 1040 Spring Street
  • Silver Spring, MD 20910
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

United Therapeutics (Priority Review Voucher) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore United Therapeutics (Priority Review Voucher)‘s full profile, request access.

Request a free trial

United Therapeutics (Priority Review Voucher) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore United Therapeutics (Priority Review Voucher)‘s full profile, request access.

Request a free trial

United Therapeutics (Priority Review Voucher) FAQs

  • Where is United Therapeutics (Priority Review Voucher) headquartered?

    United Therapeutics (Priority Review Voucher) is headquartered in Silver Spring, MD.

  • What industry is United Therapeutics (Priority Review Voucher) in?

    United Therapeutics (Priority Review Voucher)’s primary industry is Buildings and Property.

  • Is United Therapeutics (Priority Review Voucher) a private or public company?

    United Therapeutics (Priority Review Voucher) is a Private company.

  • What is the current valuation of United Therapeutics (Priority Review Voucher)?

    The current valuation of United Therapeutics (Priority Review Voucher) is .

  • What is United Therapeutics (Priority Review Voucher)’s current revenue?

    The current revenue for United Therapeutics (Priority Review Voucher) is .

  • Who are United Therapeutics (Priority Review Voucher)’s investors?

    United Therapeutics has invested in United Therapeutics (Priority Review Voucher).

  • When was United Therapeutics (Priority Review Voucher) acquired?

    United Therapeutics (Priority Review Voucher) was acquired on 19-Aug-2015.

  • Who acquired United Therapeutics (Priority Review Voucher)?

    United Therapeutics (Priority Review Voucher) was acquired by AbbVie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »